Liver is the major site of metabolism, and there are a multitude of known human genetic disorders due to hepatic deficiencies. These include phenylketonuria, glycogen storage diseases, urea cycle enzyme deficiencies, hemophilia, alpha-1-antitrypsin deficiency, etc. In these well characterized monogenic diseases, the metabolic imbalance can be restored by proper expression of the missing functions in the hepatocytes of the patients, thereby effecting a permanent cure of the disorders by hepatic gene therapy. As the human genes responsible for many of these disorders are being isolated and shown to be functional after transfection into mammalian cells, the limiting step is undoubtably the lack of suitable technologies to reintroduce these genes into the patient's liver cells. During the past several years, we and others have reported successful isolation of primary hepatocytes and demonstrated that functional genes can be efficiently transduced into them by retroviral mediated gene therapy. Most recently the feat of reintroducing these cells back into experimental animals and demonstrating long-term survival and functional of the engrafted cells in vivo has been accomplished. Primary mouse hepatocytes were effectively transplanted into recipient mice through direct injection into the portal vein or the spleen, and we demonstrated unambiguously that the engrafted hepatocytes migrate to the liver, incorporate themselves into the normal parenchyma and continue to function indefinitely in vivo. Based on this break through, we propose to 1) attempt to correct certain hepatic deficiencies in two different animal models, 2) investigate the regulation of hepatocyte growth and differentiation, and 3) explore and perfect hepatocyte transplantation technologies for larger animals. This ambitious program pulls together a group of investigators with expertise in molecular biology and genetics, cell biology and differentiation, as well as surgery and pathology, who will function as a unit to expedite the development of necessary technologies and clinical protocols for the correction of hepatic deficiencies by gene therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK044080-04
Application #
2143501
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1991-09-30
Project End
1996-08-31
Budget Start
1994-09-15
Budget End
1995-08-31
Support Year
4
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Tarlow, Branden D; Pelz, Carl; Naugler, Willscott E et al. (2014) Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell Stem Cell 15:605-18
Wu, Y; Teng, B B; Brandt, M L et al. (1999) Normal perinatal rise in serum cholesterol is inhibited by hepatic delivery of adenoviral vector expressing apolipoprotein B mRNA editing enzyme (Apobec1) in rabbits. J Surg Res 85:148-57
Muzzin, P; Eisensmith, R C; Copeland, K C et al. (1997) Hepatic insulin gene expression as treatment for type 1 diabetes mellitus in rats. Mol Endocrinol 11:833-7
Kuzmin, A I; Finegold, M J; Eisensmith, R C (1997) Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther 4:309-16
Fang, B; Wang, H; Gordon, G et al. (1996) Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther 3:217-22
Brandt, M L (1996) Gene therapy in pediatric surgery. Semin Pediatr Surg 5:197-205
Bowles, N E; Eisensmith, R C; Mohuiddin, R et al. (1996) A simple and efficient method for the concentration and purification of recombinant retrovirus for increased hepatocyte transduction in vivo. Hum Gene Ther 7:1735-42
Brandt, M L; Eckert, J W; Buerkle, C J et al. (1996) The subcutaneous spleen: a new model for percutaneous access to the portal venous system. J Invest Surg 9:161-6
Eckert, J W; Buerkle, C J; Major, A M et al. (1995) In situ hybridization utilizing a Y chromosome DNA probe. Use as a cell marker for hepatocellular transplantation. Transplantation 59:109-11
Fang, B; Eisensmith, R C; Wang, H et al. (1995) Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 6:1039-44

Showing the most recent 10 out of 25 publications